RT Journal Article
SR Electronic
T1 Effectiveness of mepolizumab in a real-life cohort of patients with severe refractory eosinophilic asthma and multiple comorbidities
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.26.20112052
DO 10.1101/2020.05.26.20112052
A1 Crimi, Claudia
A1 Campisi, Raffaele
A1 Cacopardo, Giulia
A1 Intravaia, Rossella
A1 Nolasco, Santi
A1 Porto, Morena
A1 Pelaia, Corrado
A1 Crimi, Nunzio
YR 2020
UL http://medrxiv.org/content/early/2020/06/02/2020.05.26.20112052.abstract
AB BACKGROUND Patients with severe asthma often suffer from comorbidities whose impact on the course of biological therapy has not been elucidated yet.OBJECTIVE To evaluate real-life effectiveness and the presence/absence of predictors of treatment response in patients with one or more comorbidities who received mepolizumab (MEPO) for the treatment of severe eosinophilic asthma (EA).METHODS Health records of 31 patients were retrospectively analyzed. Asthma control test (ACT) score, blood eosinophil count, forced expiratory volume in 1 second (FEV1), FEV1% of predicted and FEV1/FVC (Forced Vital Capacity) ratio, oral corticosteroid (OCS) dosage and exacerbations were recorded at baseline (T0), after 3 (T1), 6 (T3), nine (T6) and 12 months (T12). A clinical response was defined as: i) 30% exacerbation decrease; ii) 80% blood eosinophilia reduction; iii) 3 point ACT increase; iv) FEV1 increase ≥ 200 mL.RESULTS At T12 blood eosinophil level decreased by 89.89% (p>0.0001), an improvement in ACT of 3 points from baseline was recorded in 80.65% of patients (p>0.0001) and 96.77% of patients reduced by minimum 30% the number of exacerbations (p>0.0001). 84% of patients discontinued OCS (p>0.0001). FEV1 increased by 0.22 (p=0.0224) while FEV1/FVC was statistically significant only at T1. No significant differences were generally found among patients with a specific comorbidity. The number of comorbidities did not influence treatment response. Neither the comorbidities nor other characteristics (sex, BMI, age, smoking, baseline eosinophil level) influenced treatment response.CONCLUSIONS MEPO in patients with severe EA is effective regardless of the presence of one or more comorbidities.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used anonymous retrospective claims data, and as such, it did not require institutional review board review and approval or informed consent. Dr. Luigi Mancuso, secretary of the Ethical Committee of "Regione Calabria Sez. Area Centro" has certified that the collection of data regarding retrospective observational studies, which refer to outpatients treated with drugs already approved by regulatory agencies, does not need approval by Ethical Committee. The waiver N. 22/CE Regione Calabria Sex Area Centro was issued in Catanzaro, 16 January 2020. A printed copy of the waiver is available as supplemental material if needed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.ACTasthma control testEAeosinophilic asthmaECRSeosinophilic chronic rhinosinusitisFEV1forced expiratory volume in 1 secondFVCforced vital capacityGERDgastro-esophageal reflux diseaseMEPOmepolizumabNARESnonallergic rhinitis with eosinophilia syndromeOCSoral corticosteroidRCTsrandomized controlled trials